43
Active Trials
11
Phase 1
26
Phase 2
12
Phase 3
6
Therapeutic Areas
Portfolio Concentration: 105% of active trials in Oncology
Oncology
45 active / 62 total
Solid Tumor (Advanced)
8 active
2 Ph3
14 total since 2015
NSCLC
8 active
2 Ph3
9 total since 2015
Colorectal Cancer
5 active
1 Ph3
7 total since 2015
SCLC
5 active
2 Ph3
6 total since 2015
Breast Cancer
4 active
3 Ph3
5 total since 2015
Hepatocellular Carcinoma
4 active
1 Ph3
5 total since 2015
Gastric Cancer
2 active
1 Ph3
2 total since 2015
Cervical Cancer
1 active
2 total since 2015
Multiple Myeloma
1 active
1 Ph3
2 total since 2015
Melanoma
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Ovarian Cancer
1 active
1 total since 2015
HER2+ Breast Cancer
1 active
1 Ph3
1 total since 2015
Triple Negative Breast Cancer
1 active
1 Ph3
1 total since 2015
Non-Hodgkin Lymphoma
0 active
2 total since 2015
Hodgkin Lymphoma
0 active
1 total since 2015
Immunology
5 active / 8 total
CNS
1 active / 1 total
Ophthalmology
0 active / 3 total
Respiratory
0 active / 1 total
Infectious Disease
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)